{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:18Z","timestamp":1792796778281,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijbiomac.2023.129074","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T03:44:02Z","timestamp":1703907842000},"page":"129074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"P1","title":["Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule"],"prefix":"10.1016","volume":"259","author":[{"given":"Yi-Wen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Eight","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Ju","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yi","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ying","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chung","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiow-Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1742-4658.2010.07954.x","article-title":"MNB\/DYRK1A as a multiple regulator of neuronal development","volume":"278","author":"Tejedor","year":"2011","journal-title":"FEBS J."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.129074_bb0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/acsmedchemlett.0c00346","article-title":"Selective DYRK1A inhibitor for the treatment of neurodegenerative diseases: Alzheimer, Parkinson, Huntington, and down syndrome","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.129074_bb0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nbd.2005.12.006","article-title":"DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects","volume":"22","author":"Ahn","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0025","doi-asserted-by":"crossref","first-page":"15847","DOI":"10.1038\/s41598-022-19967-y","article-title":"DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-beta, tau and DYRK1A neurotoxicity","volume":"12","author":"Zhu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2015.03.004","article-title":"DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications","volume":"151","author":"Abbassi","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"48","key":"10.1016\/j.ijbiomac.2023.129074_bb0035","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of tau. A functional link between down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.129074_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3233\/JAD-130824","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression","volume":"37","author":"Qian","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","article-title":"The genetics of Alzheimer disease: back to the future","volume":"68","author":"Bertram","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1196\/annals.1332.006","article-title":"Microglia as a potential bridge between the amyloid beta-peptide and tau","volume":"1035","author":"Kitazawa","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.freeradbiomed.2020.08.030","article-title":"The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation","volume":"160","author":"Lee","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"22","key":"10.1016\/j.ijbiomac.2023.129074_bb0060","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1021\/acs.jmedchem.8b00185","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics","volume":"61","author":"Jarhad","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.129074_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13000","article-title":"Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: a potential therapeutic for Alzheimer\u2019s disease","volume":"18","author":"Melchior","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0075","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1038\/ncomms11391","article-title":"Selective inhibition of the kinase DYRK1A by targeting its folding process","volume":"7","author":"Kii","year":"2016","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.129074_bb0080","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7958","key":"10.1016\/j.ijbiomac.2023.129074_bb0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.129074_bb0090","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.129074_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cbf.3709","article-title":"Computational targeting of allosteric site of MEK1 by quinoline-based molecules","volume":"40","author":"Singh","year":"2022","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112580","article-title":"Identification and analysis of a selective DYRK1A inhibitor","volume":"146","author":"Lin","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6","article-title":"The art and practice of structure-based drug design: a molecular modeling perspective","volume":"16","author":"Bohacek","year":"1996","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0110","series-title":"Pipeline Pilot","author":"Biovia","year":"2021"},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.129074_bb0115","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0130","series-title":"Schr\u00f6dinger Release 2022\u20133: Maestro","year":"2021"},{"issue":"19","key":"10.1016\/j.ijbiomac.2023.129074_bb0135","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.bmc.2015.08.006","article-title":"Kinase hinge binding scaffolds and their hydrogen bond patterns","volume":"23","author":"Xing","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/ci050357s","article-title":"Molecular field Extrema as descriptors of biological activity: definition and validation","volume":"46","author":"Cheeseright","year":"2006","journal-title":"J. Chem. Inf. Model."},{"issue":"W1","key":"10.1016\/j.ijbiomac.2023.129074_bb0145","doi-asserted-by":"crossref","first-page":"W612","DOI":"10.1093\/nar\/gkv352","article-title":"ChEMBL web services: streamlining access to drug discovery data and utilities","volume":"43","author":"Davies","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0150","series-title":"datamol-org\/datamol: 0.7.18. Zenodo","author":"Mary","year":"2022"},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0155","unstructured":"G. Landrum, et al., rdkit\/rdkit: 2020_09_01 (Q3 2020) Release. Zenodo. https.\/\/doi.org\/10.5281\/zenodo.4107869."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0006-8993(02)03476-5","article-title":"Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation","volume":"956","author":"Lalonde","year":"2002","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.129074_bb0165","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/iub.2282","article-title":"C horizontal line Hcdots, three dots, centeredO hydrogen bonds in kinase-inhibitor interfaces","volume":"72","author":"Derewenda","year":"2020","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0170","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1038\/s41467-021-26935-z","article-title":"Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation","volume":"12","author":"Kaltheuner","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-023-01409-4","article-title":"Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases","volume":"8","author":"Song","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"16","key":"10.1016\/j.ijbiomac.2023.129074_bb0180","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1021\/jm960290n","article-title":"Neighborhood behavior: a useful concept for validation of \u201cmolecular diversity\u201d descriptors","volume":"39","author":"Patterson","year":"1996","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.129074_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/17520363.2.4.363","article-title":"Tau as a biomarker of neurodegenerative diseases","volume":"2","author":"Schraen-Maschke","year":"2008","journal-title":"Biomark. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2023.129074_bb0190","first-page":"S123","article-title":"Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration","volume":"33","author":"Wang","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.129074_bb0195","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1096\/fj.07-104539","article-title":"Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome","volume":"22","author":"Liu","year":"2008","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.129074_bb0200","doi-asserted-by":"crossref","first-page":"13556","DOI":"10.1038\/s41598-017-13786-2","article-title":"Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects","volume":"7","author":"Lathuiliere","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.129074_bb0205","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-4159.2010.06769.x","article-title":"Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between down syndrome and Alzheimer\u2019s disease","volume":"115","author":"Ryu","year":"2010","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.129074_bb0210","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","article-title":"Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease","volume":"183","author":"Wesseling","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.129074_bb0215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.129074_bb0220","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.129074_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041160","article-title":"An overview on the clinical development of tau-based therapeutics","volume":"19","author":"Medina","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.129074_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14740338.2020.1721456","article-title":"An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease","volume":"19","author":"Haake","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.129074_bb0235","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1021\/acs.jmedchem.2c02068","article-title":"Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases","volume":"66","author":"Lindberg","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2023.129074_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112770","article-title":"Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor","volume":"208","author":"Kramer","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023059731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023059731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:02:33Z","timestamp":1758884553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813023059731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"alternative-id":["S0141813023059731"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.129074","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.129074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"129074"}}